Combinations Key For Amgen’s Lumakras, But PD-1/L1 Data Held Until August

One of two highly anticipated datasets for Amgen, Inc.’s KRAS G12C inhibitor Lumakras (sotorasib) in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) was released late on 12 July when the World Conference on Lung Cancer (WCLC) published abstracts for next month’s meeting. The initial efficacy findings for use with Revolution Medicines, Inc.’s SHP2 inhibitor are inconclusive due to small NSCLC patient numbers, but the safety results appear reasonable ahead of anti-PD-1/L1 combination results being unveiled at the conference in August.

Amgen was the first company to bring a KRAS G12C inhibitor to the market and has maintained its lead even with Mirati Therapeutics, Inc.’s adagrasib following closely behind; adagrasib is under review for second-line NSCLC with a US FDA approval decision expected by December. (Also see "US FDA Puts Mirati’s KRAS Challenge To Amgen In The Slow Lane" - Scrip, 16 February, 2022.)